CCND1 and glycogen storage disease VI: t(11;14)(q13;q32) is a characteristic cytogenetic abnormality in MCL patients which leads to structural overexpression of Cyclin D1 (CCND1) on chromosome 11.[1] In recent years, rituximab-based immunochemotherapy, high-dose cytarabine-based intensive chemotherapy as well as autologous stem cell transplantation for young and eligible patients have been to proved to improve the outcome of MCL patients.[2–4] However, MCL is an invasive disease with poor prognosis.